Endo Investors is a brand that specializes in investing in game-changing early-stage companies within the life sciences industry. Their focus is on improving outcomes for large patient populations affected by chronic diseases. Formed in 2013 by Eric Edidin, Endo Investors was created in response to a lack of early-stage capital for companies working to combat global health issues, particularly diabetes.

The portfolio companies of Endo Investors have made groundbreaking breakthroughs in the areas they serve while also delivering strong investor returns. Endo Investors is backed by a group of mission-oriented investors and has a track record of supporting companies that make a significant impact on patient populations. Their portfolio includes companies such as Bigfoot Biomedical, Biolinq, Capillary Biomedical, Cecelia Health, and more.

These companies are dedicated to developing innovative solutions for insulin delivery, glucose level analysis, insulin infusions, clinical coaching, disease prevention, and treatment. With a focus on delivering improved quality of life for patients, Endo Investors is at the forefront of fostering innovation in the life sciences sector